Abstract
Mechanisms of resistance against Fas-mediated cell killing have been reported in different malignancies. However, the biological response of immune escape mechanisms might depend on malignant transformation of cancer cells. In this study we investigated different mechanisms of immune escape in 2 well-differentiated low-grade (RT4 and RT112) and 2 poorly differentiated high-grade (T24 and TCCSUP) bladder cancer cell lines. Fas, the receptor of Fas-ligand, is expressed and shedded by human transitional bladder carcinoma cell lines RT4, RT112, T24 and TCCSUP. Cytotoxicity and apoptosis assays demonstrate that in spite of the Fas expression, poorly differentiated T24 and TCCSUP cells are insensitive towards either recombinant Fas-ligand or agonistic apoptosis-inducing monoclonal antibody against Fas. In poorly differentiated T24 and TCCSUP cell lines we were able to detect marked Fas-ligand protein by flow cytometry and Western blot analysis. In grade 1 RT4 and RT112 cells only minor expression of Fas-ligand possibly because of proteinase action. Fas-ligand mRNA translation or post-translational processing seems to be regulated differentially in the cancer cell lines depending on malignant transformation. In co-culture experiments we show that poorly differentiated cells can induce apoptosis and cell death in Jurkat cells and activated peripheral blood mononuclear cells. This in vitro study suggests that bladder cancer cells can take advantage of different mechanisms of immune evasion and become more competent in avoiding immune surveillance during transformation to higher-grade malignant disease. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley A, Goodwin RG, Smith CA, Ramsdell F and Lynch DH (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181: 71–77
Arase H, Arase N and Saito T (1995) Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 181: 1235–1238
Bamberger AM, Schulte HM, Thuneke I, Erdmann I, Bamberger CM and Asa SL (1997) Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab 82: 3173–3175
Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS and Eberlein TJ (1999) Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 125: 73–84
Cascino I, Fiucci G, Papoff G and Ruberti G (1995) Three functional soluble forms of the human apoptosis-inducing Fas-molecule are produced by alternative splicing. J Immunol 154: 2706–2713
Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ and Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759–1762
Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I and Browning JL (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272: 32401–32410
Crowe DL, Boardman ML and Fong KS (1998) Anti-Fas antibody differentially regulates apoptosis in Fas ligand resistant carcinoma lines via the caspase 3 family of cell death proteases but independently of bcl2 expression. Anticancer Res 18: 3163–3170
Dhein J, Walczak H, Bäumle D, Debatin KM and Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/(FasCD95). Nature 373: 438–440
Ding EX, Hizuta A, Morimoto Y, Tanida T, Hongo T, Ishii T, Yamano T, Fujiwara T, Iwagaki H and Tanaka N (1998) Human colon cancer cells express the functional Fas ligand. Res Commun Mol Pathol Pharmacol 101: 13–24
Gastman BR, Yin XM, Johnson DE, Wieckowski E, Wang GO, Watkins SC and Rabinovich H (2000) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59: 5356–5364
Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P and Ohgaki H (1997) Fas ligand expression in human glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863–869
Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P and Ohgaki H (1998) Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 58: 2057–2062
Griffith TS, Yu X, Herndon JM, Green DR and Ferguson TA (1996) CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5: 7–16
Gruss HJ (1996) Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 26: 143–159
Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornard T, Fontana A, Lienard D, Cerottini JC and Tschopp J (1996) Melanoma cell expression of Fas (APO-1/CD95) ligand: Implication for tumor immune escape. Science 274: 1363–1366
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388: 190–195
Itoh N, Tsujimoto Y and Nagata S (1993) Effect of bcl-2 on Fas-antigen mediated cell death. J Immunol 151: 621–6227
Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H and Golstein P (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxcicity. Science 265: 528–530
Kayagaki NA, Kawasaki T, Ebata H, Ohmoto S, Ikeda S, Yoshino K, Okumura K and Yagita H (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777–1783
Klas C, Debatin KM, Jonker RR and Krammer PH (1993) Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 5: 625–630
Lee SH, Lee JY, Park WS, Kim SY, Jang JJ and Yoo NJ (1999) Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int 83: 698–702
Liu C, Cheng J and Mountz J (1995) Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. J Biochem 310: 957–963
Midis GP, Shen Y and Owen-Schaupp LB (1996) Elevated soluble Fas (sFas) in nonhematopoetic human malignancy. Cancer Res 56: 3870–3874
Mitsiades N, Poulaki V, Kotoula V, Leone A and Tsokos M (1998) Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 153: 1947–1956
Mizutani Y, Yoshida O and Bonavida B (1998) Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol 160: 571–576
Mizutani Y, Yoshida O and Miki T (1999) Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. J Urol 62: 2170–2175
Moers C, Warskulat U, Muschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW and Haussinger D (1999) Regulation of CD95 (Fas/APO-1) ligand and receptor expression in squamous cell carcinoma by interferon-γ and cisplatin. Int J Cancer 80: 564–572
Muschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW and Haussinger D (1999) CD95 ligand expression in dedifferentiated breast cancer. J Pathol 189: 378–386
Nagata S (1997) Apoptosis by death factor. Cell 88: 355–365
Nakamura S, Takeshima M, Nakamura Y, Ohtake S and Matsuda T (1997) Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Anticancer Res 17: 173–179
Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C and Levero M (1995) Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 10: 1157–1164
Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR and Kratzke RA (1997) Human lung carcinoma express Fas ligand. Cancer Res 57: 1007–1012
O’Connell J, O'sullivan GC, Collins JK and Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075–1082
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzaw A, Kasugai T, Kitamura Y, Itoh N, Suda T and Nagata S (1993) Lethal effect of the anti-Fas-antibody in mice. Nature 364: 806–809
Owen-Schaub LB, Radinsky R, Kruzel E, Berry K and Yonehara S (1994) Anti-Fas on non-hematopoetic tumors: levels of Fas/APO-1 and bcl-2 are not predicive of biological responsiveness. Cancer Res 54: 1580–1586
Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesener TG and Bartos DP (1995) Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. 94: 1–8
Powell WC, Fingleton B, Wilson CL, Boothby M and Matrisian LM (1999) The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9: 1441–1447
Runic R, Lockwood CJ, Ma Y, Dipasquale B and Guller S (1996) Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endocrinol Metab 81: 3119–3122
Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME (1998) Apoptosis signaling by death receptors. Eur J Biochem 254: 439–459
Shiraki K, Tsuji N, Shioda T, Isselbacher KJ and Takahashi H (1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94: 620–625
Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells – A mechanism of immune evasion?. Nature Med 12: 1361–1366
Suda T, Takahashi T, Golstein P and Nagata S (1993) Molecular cloning and expression of the Fas-ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169–1178
Suda T, Hashimoto H, Tanaka M, Ochi T and Nagata S (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes and soluble Fas ligand blocks the killing. J Exp Med 186: 2045–2050
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315–5320
Tanaka M, Suda T, Takahashi T and Nagata S (1995) Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO 14: 1129–1135
Thilenius AR, Braun K and Russel JH (1997) Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Eur J Immunol 27: 1108–1114
Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B and Kalthoff H (1998) Human pancreatic adenocarcinomas express Fas and Fas Ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58: 1741–1749
Von Reyher U, Sträter J, Kittstein W, Gschwendt M, Krammer PH and Möller P (1998) Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58: 526–534
Wang J and Lenardo MJ (1997) Molecules involved in cell death and peripheral tolerance. Curr Opin Immunol 9: 818–825
Weller M, Malipiero U, Aguzzi A, Reed JC and Fontana A (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and conferes resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633–2643
Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, Ueno N, Nishida E, Shibuya H and Matsumoto K (1999) XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO 18: 179–187
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Perabo, F., Kamp, S., Schmidt, D. et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer 84, 1330–1338 (2001). https://doi.org/10.1054/bjoc.2001.1808
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1808
Keywords
This article is cited by
-
The immunoregulatory mechanisms of carcinoma for its survival and development
Journal of Experimental & Clinical Cancer Research (2011)
-
Strategies for molecular expression profiling in bladder cancer
Cancer and Metastasis Reviews (2009)
-
Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes
BMC Cancer (2005)
-
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer
Cancer Gene Therapy (2005)